lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p

Peng, Yi; Huang, Xiaoxi; Wang, Hongmei

doi:10.1186/s12860-022-00432-7

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinical setting, drug resistance is a signi cant challenge for late-stage TNBC treatment (37,38). Currently, the lack of speci c targeted therapies for TNBC has prompted an increased focus on nding precise and speci c biomarkers, as well as identifying new treatment targets (39,40). LncRNAs have gradually become a research hotspot due to their unique characteristics, and increasing evidence has con rmed the ability of lncRNAs and miRNAs to predict the diagnosis and prognosis and regulate the development of TNBC and other malignant tumors (7,(40)(41)(42)(43)(44).…”

Section: Discussionmentioning

confidence: 99%

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Ye,

Fan,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play important regulatory roles in the progression of kinds of cancers. However, the biological roles of most lncRNAs in breast cancer, especially TNBC, remain unclear. In this study, we investigated the functional of a novel lncRNA, named lncRNA EWSAT1, in the breast cancer and the underlying molecular mechanisms. EWSAT1 was significantly upregulated in the triple negative breast cancer (TNBC) tissues compared with adjacent normal tissues in the GEO databases. We verified the upregulated level of EWSAT1 in the TNBC patients’ serums compared with healthy serums, which also associated with clinical diagnosis. Bioinformatics analysis demonstrated that microRNA (miR)-330-5p was a potential target of SEAS1. Dual luciferase reporter assays confirmed that EWSAT1 functioned as a sponge for miR-330-5p, regulating the expression of BCL2L2. Moreover, RT-qPCR demonstrated that EWSAT1 negatively regulated the expression of miR-330-5p, and positively regulated the expression of BCL2L2 at transcription and protein level. CCK-8 demonstrated that EWSAT1 could inhibit the viability of TNBC cells. In conclusion, our studies find a functional lncRNA EWSAT1 in the TNBC, and reveal a novel pathway for TNBC treatment via EWSAT1/miR-330-5p/BCL2L2, and suggest EWSAT1 might be a potential biomarkers for TNBC diagnosis and therapeutic target for TNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

Ye,

Fan,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

MicroRNA-532 as a probable diagnostic and therapeutic marker in cancer patients

Lotfi,

Maharati,

Hamidi

et al. 2024

Mutation Research - Fundamental and Molecular Mechanisms of Mut

View full text Add to dashboard Cite

Heterogeneity of the Alpha-Smooth Muscle Actin Tumor Score in Breast Cancer Cells Significantly Affects Tumor Invasiveness, Recurrence, and Patient Survival

Pasca Fenesan,

Cosma,

Melnic

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Alpha-smooth muscle actin (αSMA) has been widely investigated in malignancies, primarily concerning its expression in cancer-associated fibroblasts (CAFs) inside the tumor stroma. Microscopic examination indicates that αSMA expression is not confined to the tumor stromal compartment but is also present in a subset of tumor cells, and this expression correlates with an enhanced invasive phenotype of malignant cells from lung, liver, or ovarian malignancies. Information on actin expression in breast cancer (BC) cells is scarce, and its influence on clinicopathological characteristics remains ambiguous due to conflicting findings in the literature. Objective: To examine the αSMA tumor score in breast cancer cells utilizing digital image analysis (DIA) methodologies and to critically analyze the varying effects of αSMA tumor score values on clinicopathologic parameters, particularly focusing on tumor cell invasiveness, recurrence, and survival. Materials and methods: Double immunostaining for CD34 and αSMA was conducted on 53 breast cancer cases that were thoroughly characterized in relation to clinicopathologic data. Double immunostaining for CD34 and αSMA demonstrated different distribution patterns of both markers in normal and breast cancer tissues. DIA data about αSMA tumor cell density, intensity, tumor score, and histological score were correlated with clinicopathological factors. Results: We delineated three unique breast cancer subgroups based on αSMA tumor scores: a 9.43% low-expressing subgroup (αSMA_TS low , score 4), a 35.07% medium-expressing subgroup (αSMA_TS med , scores 5 and 6), and a 55.5% high-expressing subgroup (αSMA_TS high , scores 7 and 8). Stromal immature vessels and tertiary lymphoid structures (TLS) exhibited a strong correlation with αSMA_TS low , whereas recurrence, perineural, and lymphovascular invasion strongly influenced the αSMA_TS med and αSMA_TS high subgroups. The αSMA_TS med subgroup demonstrated the most heterogeneity with the influence of αSMA-expressing breast cancer cells on tumor size, nodal status, perineural and lymphovascular invasion, menopausal status, recurrence, and survival. Most of the cases from the αSMA_TS low subgroup had Luminal B and Luminal B-HER2 phenotypes, while triple-negative breast cancer (TNBC) represented one-third of all cases in the αSMA_TS high subgroup. Conclusion: αSMA-expressing breast cancer cells variably affect malignant growth, invasion, and recurrence, highly contingent upon their density and expression intensity. The current investigation identified an αSMA_TS med BC subgroup that appears to promote invasiveness, recurrence, and survival in breast cancer. Our data indicate that αSMA BC-expressing cells play a dual role in BC progression, contingent upo...

show abstract

lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p

Cited by 3 publications

References 26 publications

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

LncRNA Inhibits the Viability of Triple-Negative Breast Cancer (TNBC) by Targeting the miR-330-5p/BCL2L2 Axis

MicroRNA-532 as a probable diagnostic and therapeutic marker in cancer patients

Heterogeneity of the Alpha-Smooth Muscle Actin Tumor Score in Breast Cancer Cells Significantly Affects Tumor Invasiveness, Recurrence, and Patient Survival

Contact Info

Product

Resources

About